Veeva Partners with Amgen to Revolutionize Clinical Trial Processes

In a significant move aimed at enhancing clinical trials, Veeva Systems, a leader in cloud solutions for the life sciences industry, has announced a collaboration with Amgen, one of the foremost biotechnology companies globally. This partnership, revealed on August 28, 2025, seeks to leverage Veeva's advanced technologies to improve the efficiency and effectiveness of clinical trial operations.

Amgen, recognized for its commitment to developing innovative medicines, will incorporate the Veeva Clinical Platform into its processes. This platform allows Amgen to streamline and optimize its clinical operations, thereby delivering new treatments more rapidly to patients suffering from severe illnesses. According to Scott Skellenger, Senior Vice President and Chief Information Officer at Amgen, this collaboration marks a pivotal step in utilizing cutting-edge technology to enhance trial operations. He expressed that the partnership is expected to reinforce Amgen's capacity to provide rapid and scalable solutions to bring innovative therapies to market.

Jim Reilly, President of Veeva Development Cloud, remarked on the impact of this cooperation: "We are thrilled to support Amgen in its quest to advance clinical development. The Veeva Clinical Platform will serve as a foundational element for standardized and interconnected processes, which are crucial for expediting the delivery of life-saving drugs to those in need."

The Veeva Clinical Platform

The Veeva Clinical Platform stands out as a comprehensive, integrated system that encompasses various components essential for clinical trials. This includes Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), clinical workbench (CDB), Randomization and Trial Supply Management (RTSM), electronic Clinical Outcome Assessment (eCOA), electronic Trial Master File (eTMF), Site Connectivity, and training for studies. By connecting these tools, the platform aims to create a seamless data flow, which is crucial for effective trial management.

Veeva's commitment to technology is evident in its focus on innovation to meet the evolving needs of the life sciences sector. With over 1,500 clients ranging from large biopharmaceutical firms to new biotech startups, Veeva's solutions are designed to enhance productivity and improve outcomes in drug development. The company operates as a Public Benefit Corporation, balancing the interests of stakeholders, including customers, employees, and the wider community.

The Future of Clinical Trials

This collaboration between Veeva and Amgen is not just about immediate improvements; it anticipates future advancements in how clinical trials are conducted globally. The integration of Veeva's tools positions Amgen to respond swiftly to emerging challenges in clinical research, addressing the complexities of modern drug development with agility and precision.

As the healthcare landscape transforms with advanced technologies, partnerships like that of Veeva and Amgen pave the way for more efficient drug development processes, which ultimately benefit patients around the world.

For additional details about the Veeva Clinical Platform, interested parties can find more information on Veeva's website at veeva.com. This innovative collaboration is anticipated to set new standards in clinical trials, with the potential to inspire further advancements across the healthcare industry.